Both EMPA-REG OUTCOME (Empalifilozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes) and CANVAS (Canagliflozin Cardiovascular Assessment Study) trials found that in individuals with type 2 diabetes, use of SGLT-2 inhibitors was associated with a reduction in death from cardiovascular causes, hospitalization for heart failure, and all-cause mortality when compared with placebo (59–61). This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.